Identification of prognosis biomarkers of prostatic cancer in a cohort of 498 patients from TCGA.
Prostatic cancer (PCa) is the first common cancer in male, and the prognostic variables are beneficial for clinical trial design and treatment strategies for PCa. This study was performed to identify more potential biomarkers for the prognosis of patients with PCa. The transcriptome data and survival information of a cohort including 498 subjects with PCa were downloaded from TCGA. A total of 4293 differentially expressed genes (DEGs), including 1362 prognosis-related DEGs, were identified in PCa tissues compared with normal tissues. Upregulated genes, including serine/arginine-rich splicing factors (SRSFs; such as SRSF2, SRSF5, SRSF7 and SRSF8), and ubiquitin conjugating enzyme E2 (UBE2) members (such as UBE2D2, UBE2G2, UBE2J1 and UBE2E1), were identified as negative prognostic biomarkers of PCa, as the high expression of them correlated with poor overall survival of PCa patients. Several downregulated Golgi-ER traffic mediators (such as SEC31A, TMED2, and TMED10) were identified as positive prognostic biomarkers of PCa, as the high expression of them correlated with good overall survival of PCa patients. These genes were of great interests in prognosis of PCa, and some of them may be constructive for the augmentation of clinical trial design and treatment strategies for PCa.